The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

A new study published in the journal of Arthritis and Rheumatology showed that the combination of zimlovisertib and ...

Although osteoarthritis is receiving more attention in both the research and clinical arenas than ever, all that attention ...

BACKGROUND: Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

The FDA has granted orphan drug status to rilzabrutinib, an investigational therapy to prevent pain crises in sickle cell ...